Nkarta, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 1.56 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 111.73M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Details
| Name | Nkarta, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 106 |
| Founded | 2015 |
| Ipo Date | 2020-07-10 |
| Ceo | Paul Hastings |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 18.00 |
| Isin | US65487U1088 |
| Cusip | 65487U108 |
| Cik | 1787400 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Paul J. Hastings | Chief Executive Officer and Director |
| Dr. Nadir Mahmood Ph.D. | President and Principal Accounting and Financial Officer |
| Dr. Shawn Rose M.D., Ph.D. | Chief Medical Officer and Head of Research and Development |
Contact
| Address | 1150 Veterans Boulevard, South San Francisco, California 94080, United States |
| Phone | 925 407 1049 |
| Website | https://www.nkartatx.com |